Search

ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models

November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

VIRTUAL: EHA-TSH Hematology Tutorial

June 25&26, 2021

Meeting Chairs:

Prof S Eichinger (European Hematology Association)
Prof H Özsan (Turkish Society of Hematology)
In close collaboration with the Turkish Society of Hematology, EHA has annually organized  live, joint tutorials (nine in the series), which are organized as part of…

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

SWG Educational Activities

EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).

Read more

Session information—March 13, 2025

Topic'Primary Immunodeficiencies in Pediatric Hematooncology Practice. '

Speaker detailsCamilla Visconti (speaker)Dr Camilla Visconti is a final-year fellow in the Pediatric Immunology and BMT Unit at San Raffaele Hospital in Milan, where she manages children with inborn errors of immunity.

Read more

EHA Statement: Our sustained solidarity with the hematology community in Ukraine

Friday, February 24 marks one year of war. The European Hematology Association (EHA) stands in solidarity with our colleagues and friends in Ukraine.

Read more